Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage I-III HER2-positive breast cancer: Results of a single-arm pilot clinical trial

被引：0
|
作者：
Jiang, Jun [1 ]
机构：
[1] Army Med Univ, Chongqing, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS11-24
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Imai, Aya
    Okamoto, Akiko
    Hamaoka, Asako
    Soushi, Mari
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Goto, Mariko
    Yamada, Kei
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 92 - 97
  • [32] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Aya Imai
    Akiko Okamoto
    Asako Hamaoka
    Mari Soushi
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Mariko Goto
    Kei Yamada
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 92 - 97
  • [33] PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Shi, Qiyun
    Xuhong, Juncheng
    Luo, Tao
    Ge, Jia
    Liu, Feng
    Lan, Yang
    Chen, Qingqiu
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Liang, Yan
    Wang, Minghao
    Hu, Ying
    Zhang, Yi
    Bian, Xiuwu
    Qi, Xiaowei
    Jiang, Jun
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 121 - 129
  • [34] PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Qiyun Shi
    Juncheng Xuhong
    Tao Luo
    Jia Ge
    Feng Liu
    Yang Lan
    Qingqiu Chen
    Peng Tang
    Linjun Fan
    Li Chen
    Yan Liang
    Minghao Wang
    Ying Hu
    Yi Zhang
    Xiuwu Bian
    Xiaowei Qi
    Jun Jiang
    British Journal of Cancer, 2023, 128 : 121 - 129
  • [35] Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
    Pierga, Jean-Yves
    Petit, Thierry
    Delozier, Thierry
    Ferrero, Jean-Marc
    Campone, Mario
    Gligorov, Joseph
    Lerebours, Florence
    Roche, Henri
    Bachelot, Thomas
    Charafe-Jauffret, Emmanuelle
    Pavlyuk, Maria
    Kraemer, Sandrine
    Bidard, Francois-Clement
    Viens, Patrice
    LANCET ONCOLOGY, 2012, 13 (04): : 375 - 384
  • [36] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
  • [37] Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial
    Man, Xiaochu
    Huang, Jie
    Sun, Shujuan
    Zhou, Dongdong
    Zhang, Baoxuan
    Fang, Shu
    Zheng, Fangchao
    Li, Chao
    Wang, Xinzhao
    Huang, Wei
    Wang, Linlin
    He, Qingqing
    Fu, Hui
    Zhang, Yan
    Liu, Changrui
    Dong, Lin
    Zhao, Xianguang
    Xu, Liang
    Sun, Xiao
    Fan, Bingjie
    Song, Lihua
    Zhou, Zhengbo
    Yu, Jinming
    Li, Huihui
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (05):
  • [38] Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression
    Khan, Qamar J.
    O'Dea, Anne
    Fabian, Carol J.
    Connor, Carol Sue
    McGinness, Marilee
    Mammen, Joshua Matthew Varghise
    Wagner, Jamie Lynn
    Baccaray, Stella
    Springer, Michelle
    Yeh, Henry
    Sharma, Priyanka
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
    Xu, B.
    Yan, M.
    Ma, F.
    Li, W.
    Ouyang, Q.
    Tong, Z.
    Teng, Y.
    Wang, S.
    Wang, Y.
    Geng, C.
    Luo, T.
    Zhong, J.
    Zhang, Q.
    Liu, Q.
    Zeng, X.
    Sun, T.
    Mo, Q.
    Dong, F.
    Wu, S.
    Zhu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1387 - S1387
  • [40] Neoadjuvant pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with HER2-positive early breast cancer: A single-group, multicenter, phase II study
    Liu, Z.
    Zhu, J.
    Wang, C.
    Sun, X.
    Lu, Z.
    Chen, X.
    Wang, H.
    Mao, S.
    Zhou, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S331 - S331
12345